Financials
Financial year 2025
Worth noting
- Figures corrected afterwards (2023, 2024).
Gross margin
€ -1.5 million
▲ 32% vs 2024
Profit
Caution€ -5.7 million
▼ 423% vs 2024
Debts
Low€ 9.6 million
▲ 187% vs 2024
Ncardia Holding from Mont-Saint-Guibert, company number BE0565979162, closed financial year 2025 with a result of € -5.7 million after tax. For that financial year Ncardia Holding recorded a gross margin of € -1.5 million and equity of € 98.8 million. Compared with financial year 2024, the result moved from € 1.8 million to € -5.7 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 10, 2026.
What happened at Ncardia Holding?
What happened at Ncardia Holding in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Tim Van Biesen stepped down as director. NBB
- BioPharma Management and Consulting SRL stepped down as director. NBB
- Nicholas 0'Leary stepped down as director. NBB
- Geoffrey Glass stepped down as director. NBB
- Jason Conner stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 5.7 million (▼ 423% vs 2024). Source: NBB ↗
- Jason Conner became a director. NBB
- Tim Van Biesen became a director. NBB
In short
From € 13.7 million loss in 2021 to € 5.7 million loss in 2025.
Paid € 553,628 in corporate taxes since 2021.
Best year ever: 2024, with € 1.8 million profit.
A new publication or filing at Ncardia Holding? We notify you, reason included.
Follow Ncardia HoldingNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
It owns 0% of NCardia US Inc., 0% of Ncardia B.V., 0% of Cellistic NV and 0% of Celyntra Therapeutics itself.
Directors
According to the 2025 annual accounts
BioPharma Management and Consulting SRL
Director · represented by Denis Bedoret
since 2021 · until 2027
Nicholas 0'Leary
Director
since 2021 · until 2027
Geoffrey Glass
Director
since 2021 · until 2027
since 2026 · until 2027
Tim Van Biesen
Director
since 2024 · until 2030
Establishments
Establishment units
Physical locations of this company
Rue Edouard Belin 2
1435 Mont-Saint-Guibert
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
Details
- Company number
- 0565.979.162
- VAT number
- BE 0565.979.162
- Registered office
- Rue Edouard Belin 2, 1435 Mont-Saint-Guibert
- Names & denominations
- Ncardia Holding
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 28 October 2014
- Peppol
- Active · Active since 2 Dec 2025
- Contact
- ncardia.com investors@ncardia.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Administratieve en ondersteunende activiteiten ten behoeve van kantoren
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige technische testen en toetsen
Overige zakelijke dienstverlening, neg
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
+1